Declining use and spending on TG-lowering therapies has been reported among beneficiaries of the Medicare Part D prescription drug plan in a cross-sectional study of trends from 2013-2021. Using the Medicare database, the researchers assessed annual expenditure for all generic and brand name formulations of fibrates, omega-3 acid ethyl esters and niacin, together with the number of beneficiaries.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
